The revolutionary GLP-1 class of weight loss drugs are racking up blockbuster sales at a pace rarely seen in the pharmaceutical industry. But the pharma industry’s gain is the food industry’s loss. Read more...
Site référencé: Quartz
weight loss, morgan stanley, anti obesity medication, health medical pharma, glp 1 receptor agonists, ozempic, glucagon like peptide 1, peptide therapeutics, glp 1, smithfield foods, sc johnson, semaglutide, obesity, wegovy, novo nordisk, peptide hormones, anti diabetic drugs, shane smith, social issues, addiction
Quartz
Honda and Nissan are getting hammered — and they can't blame tariffs yet
13/05/2025
Inflation cools. What the CPI report says about the economy
13/05/2025
Boeing gets a break in China
13/05/2025
UnitedHealth Group just switched CEOs and nixed its 2025 guidance
13/05/2025
United Airlines CEO says Newark Airport is 'absolutely safe'
13/05/2025
Coinbase is joining the S&P 500 in a big moment for crypto — and the stock soars
13/05/2025
